2023_Apr_HW_LNP_Boston_skyscraper

Industrialising Drug Delivery99

Issue No #99 Aug 2019 August 15th, 2019

Inside the magazine

PERSONALISING DRUG PRODUCTS USING 3D PRINTING

Sarah Trenfield

PERSONALISING DRUG PRODUCTS USING 3D PRINTING

Sarah Trenfield and Abdul Basit look at the potential applications of 3D-printing technology to create personalised drug therapies in fields such as multiple drug therapy and paediatric/geriatric care and introduce FabRx’s 3D-printing system, which can produce formulations to suit a variety of situations.

EXPANDING AUTOMATION CAPACITY FOR HIGH AND LOW VOLUMES

INDUSTRIALISATION

Gilbert Fluetsch

EXPANDING AUTOMATION CAPACITY FOR HIGH AND LOW VOLUMES

Gilbert Fluetsch and Lucy Chung look at how automation and assembly services can best evolve and adapt to industry standards and market demands, whilst delivering consistently at high quality and in a timely manner.

Z.BLIZZARD AUTOMATION SYSTEM – IT DOESN’T GET MORE TAILOR-MADE THAN THIS

INDUSTRIALISATION

Berthold Schopferer

Z.BLIZZARD AUTOMATION SYSTEM – IT DOESN’T GET MORE TAILOR-MADE THAN THIS

Berthold Schopferer explains how the Zahoransky’s integrated syringe manufacturing and assembly equipment allows maximum customisation and full customer involvement.

3D PRINTING DRUGS: LEARNING FROM THE PIONEERS

3D PRINTING DRUGS: LEARNING FROM THE PIONEERS

Jamie Clayton reviews the potential of 3D printing as a pharmaceutical production method and looks at the associated implications for formulation development, focusing on powder-based printing. He examines what leading experts now understand about how to specify powder feeds for 3D printing.

COMPACTION SIMULATION / INDUSTRIAL PRESS CORRELATION: TWO CASE STUDIES

Dr Aline Moulin

COMPACTION SIMULATION / INDUSTRIAL PRESS CORRELATION: TWO CASE STUDIES

Aline Moulin and Lucile Kowalski examine two case studies comparing compaction simulation with industrial compression.

INDUSTRIALISATION OF INHALATION PRODUCTS: OVERCOMING HURDLES AT COMMERCIAL SCALE

INDUSTRIALISATION OF INHALATION PRODUCTS: OVERCOMING HURDLES AT COMMERCIAL SCALE

Robin Heath discusses the typical challenges in scaling-up drug products from small-scale production to commercial manufacturing – and how these can be overcome.

Cecile Halte, BD

BD (Becton Dickinson & Company)

Cecile Halte, BD

In this interview, Cécile Halté, Senior Program Manager, Acute Care Segment, for BD Medical – Pharmaceutical Systems. discusses validation studies of the BD Sterifill Advance™ plastic prefilled syringe, which is intended for use in the hospital setting by healthcare professionals either for manual bolus injections, or with infusion pumps.

Bob Tilling, Kallik

Bob Tilling, Kallik

In this interview, Bob Tilling, Business Development Manager at Kallik, shares his insights on best practice for factory labelling.

A FIVE-STEP APPROACH TO INNOVATION IN DRUG DELIVERY SYSTEMS

INDUSTRIALISATION

Michael Wiglenda

A FIVE-STEP APPROACH TO INNOVATION IN DRUG DELIVERY SYSTEMS

Michael Wiglenda explains Gerresheimer’s industrialisation offering and the five-step Gate-Model that guides its innovation process.

QUALI-V EXTRA DRY: A NOVEL CAPSULE FOR DELIVERING HYGROSCOPIC FORMULATIONS

INDUSTRIALISATION

Jose Luis Encinas

QUALI-V EXTRA DRY: A NOVEL CAPSULE FOR DELIVERING HYGROSCOPIC FORMULATIONS

Jose Luis Encinas and Susana Ecenarro explore how the use of Quali-V^® Extra Dry capsules can help improve product stability and, crucially, lead to efficiencies and savings in drug product manufacture.

AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION

INDUSTRIALISATION

AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION

Steve Wardell and Catherine Thacker explore how machine learning technology is enabling the automation of challenging, or previously impossible, manual inspections.

SYNERGISING EXCIPIENTS TO BOOST SKIN DELIVERY

SYNERGISING EXCIPIENTS TO BOOST SKIN DELIVERY

Cécile Morin and Delphine Marchaud discuss combining polar and apolar excipients in topical formulations in order produce synergies that maximise the performance of the drug.

Top